{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dalfopristin
to a specific field?
There is one exact (name or code) match for dalfopristin
Status:
US Approved Rx
(1999)
Source:
NDA050748
(1999)
Source URL:
First approved in 1999
Source:
NDA050748
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Dalfopristin is a pristinamycin-like component of anti-bacterial drug called Synercid which also containes quinupristin (quinupristin:dalfopristin ratio is 30:70 (w/w)). The drug was approved by FDA and used for the treatment of skin diseases caused by Staphylococcus aureus or Streptococcus pyogenes. Dalfopristin binds to the RNA of the 50S ribosomal subunit and thus inhibits the late phase of protein synthesis.
Showing 1 - 4 of 4 results
Status:
US Approved Rx
(1999)
Source:
NDA050748
(1999)
Source URL:
First approved in 1999
Source:
NDA050748
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Dalfopristin is a pristinamycin-like component of anti-bacterial drug called Synercid which also containes quinupristin (quinupristin:dalfopristin ratio is 30:70 (w/w)). The drug was approved by FDA and used for the treatment of skin diseases caused by Staphylococcus aureus or Streptococcus pyogenes. Dalfopristin binds to the RNA of the 50S ribosomal subunit and thus inhibits the late phase of protein synthesis.
Status:
US Approved Rx
(1999)
Source:
NDA050747
(1999)
Source URL:
First approved in 1999
Source:
NDA050747
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Quinupristin is an antibiotic compound and a semisynthetic derivative of pristinamycin Ia. Quinupristin is a combination of three peptide macrolactones. Quinupristin is used in combination with dalfopristin, another antibiotic, under the trade name Synercid. Synercid is indicated for treatment of complicated skin and skin structure infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes. The mechanism of action of quinupristin is inhibition of the late phase of protein synthesis in the bacterial ribosome. Quinupristin binds to 23S rRNA within the 50S ribosomal subunit and prevents elongation of the polypeptide as well as causing incomplete chains to be released. Adverse reactions to Synercid include inflammation at infusion site, rash, nausea, vomiting and others.
Status:
Possibly Marketed Outside US
Source:
Virginiamycin by Phibro Saúde Animal Internacional Ltda.
Source URL:
First approved in 2007
Source:
Virginiamycin by Phibro Saúde Animal Internacional Ltda.
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(1999)
Source:
NDA050748
(1999)
Source URL:
First approved in 1999
Source:
NDA050748
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Dalfopristin is a pristinamycin-like component of anti-bacterial drug called Synercid which also containes quinupristin (quinupristin:dalfopristin ratio is 30:70 (w/w)). The drug was approved by FDA and used for the treatment of skin diseases caused by Staphylococcus aureus or Streptococcus pyogenes. Dalfopristin binds to the RNA of the 50S ribosomal subunit and thus inhibits the late phase of protein synthesis.
